Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
11
2021
accepted:
09
01
2023
entrez:
9
2
2023
pubmed:
10
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
The anti-fibrotic effect of metformin has been widely demonstrated. Fibrosis in the kidney after injury is associated with reduced expression of genes involved in both fatty acid and glycolytic energy metabolism. We have previously reported that the anti-fibrotic effect of metformin requires phosphoregulation of fatty acid oxidation by AMP-activated protein kinase (AMPK). To determine whether metformin also acts via regulation of glycolysis, we mutated regulatory phosphosites in the PFKFB2 isoform of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB2), a key regulator of glycolysis in the kidney. Mice with inactivating knockin (KI) mutations of the phosphorylation sites in PFKFB2 (PFKFB2 KI mice), which reduces the ability to increase the rate of glycolysis following stimulation, were used. Metformin was administered via drinking water to mice with a unilateral ureteric obstruction (UUO) model of renal fibrosis. In the PFKFB2 KI mice treated with metformin, there was decreased fibrosis and macrophage infiltration following UUO as assessed by Western blot for fibronectin and RT-PCR for α-smooth muscle actin, collagen 3, and F4.80, and confirmed by histology. Expression of the inducible PFKFB3 isoform was increased with metformin in UUO in both WT and PFKFB2 KI mice. There was no significant difference between WT and PFKFB2 KI mice treated with metformin in the degree of fibrosis following UUO in any of the Western blot or RT-PCR parameters that were measured. These data show that inhibition of the regulation of glycolysis by PFKFB2 does not diminish the anti-fibrotic effect of metformin in a model of renal fibrosis.
Identifiants
pubmed: 36757995
doi: 10.1371/journal.pone.0280792
pii: PONE-D-21-37485
pmc: PMC9910667
doi:
Substances chimiques
Metformin
9100L32L2N
Pfkfb2 protein, mouse
EC 2.7.1.105
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0280792Informations de copyright
Copyright: © 2023 Harley et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cold Spring Harb Symp Quant Biol. 2011;76:211-6
pubmed: 22096029
PLoS One. 2012;7(1):e29887
pubmed: 22253816
FEBS Lett. 2003 Nov 20;554(3):264-70
pubmed: 14623077
Nat Med. 2015 Jan;21(1):37-46
pubmed: 25419705
Sci Rep. 2020 Sep 3;10(1):14531
pubmed: 32884050
Mol Cancer. 2018 Feb 19;17(1):35
pubmed: 29455645
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3047-52
pubmed: 10077634
Mol Cell Endocrinol. 2015 Sep 5;412:116-22
pubmed: 26067231
Sci Rep. 2016 Apr 07;6:23975
pubmed: 27052588
Mol Endocrinol. 1997 Apr;11(4):490-502
pubmed: 9092801
Gene. 2001 Feb 7;264(1):131-8
pubmed: 11245987
Am J Physiol Renal Physiol. 2017 Feb 1;312(2):F323-F334
pubmed: 27465995
Biochem J. 2004 Aug 1;381(Pt 3):561-79
pubmed: 15170386
Nephron Exp Nephrol. 2014 Dec 6;:
pubmed: 25503637
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Biol Chem. 2002 Feb 22;277(8):6183-7
pubmed: 11744734
J Am Soc Nephrol. 2018 Sep;29(9):2326-2336
pubmed: 29976587
J Cell Physiol. 2018 Sep;233(9):7045-7054
pubmed: 29380373